10-Q 1 bolt-20240331.htm 10-Q 10-Q
false0001641281Q1--12-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2021-01-012021-01-310001641281us-gaap:CommercialPaperMember2023-12-310001641281us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310001641281srt:MaximumMemberbolt:InnoventAgreementMember2024-01-012024-03-3100016412812023-01-012023-03-310001641281us-gaap:CommonStockMember2023-12-310001641281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281bolt:InnoventAgreementMember2024-01-012024-03-310001641281us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001641281bolt:GenmabAgreementMember2021-05-012021-05-310001641281us-gaap:OtherIncomeMemberbolt:InnoventAgreementMember2024-01-012024-03-310001641281bolt:TwoThousandTwentyOneEquityIncentivePlanMemberus-gaap:CommonStockMember2022-12-312022-12-310001641281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281bolt:TorayDevelopmentAgreementMember2023-12-310001641281us-gaap:AssetBackedSecuritiesMember2023-12-310001641281us-gaap:CommercialPaperMember2024-03-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001641281bolt:ChesapeakeMasterLeaseMember2021-06-012021-06-300001641281bolt:ChesapeakeMasterLeaseMember2023-01-012023-03-310001641281us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001641281us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-01-010001641281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-03-310001641281us-gaap:USTreasurySecuritiesMember2024-03-310001641281srt:MaximumMemberus-gaap:SubsequentEventMember2024-05-142024-05-140001641281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:CommonStockMember2024-01-012024-03-310001641281bolt:GenmabAgreementMember2024-03-310001641281us-gaap:AdditionalPaidInCapitalMember2023-03-310001641281us-gaap:CommonStockMember2022-12-3100016412812024-01-012024-03-310001641281us-gaap:EquipmentMember2024-03-310001641281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:RetainedEarningsMember2023-03-310001641281us-gaap:USTreasurySecuritiesMember2023-12-310001641281us-gaap:AdditionalPaidInCapitalMember2024-03-310001641281bolt:TorayDevelopmentAgreementMember2024-03-310001641281us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2021-01-310001641281bolt:ChesapeakeMasterLeaseMember2020-08-070001641281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-3100016412812023-12-310001641281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2024-03-310001641281us-gaap:USTreasurySecuritiesMember2024-03-310001641281us-gaap:CorporateDebtSecuritiesMember2023-12-310001641281us-gaap:CorporateDebtSecuritiesMember2024-03-310001641281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-3100016412812024-03-310001641281us-gaap:RetainedEarningsMember2023-01-012023-03-310001641281bolt:ShelfRegistrationAndAtTheMarketEquityOfferingMemberbolt:CowenAndCompanyLlcMemberus-gaap:CommonStockMember2022-03-302022-03-300001641281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-03-310001641281bolt:TorayDevelopmentAgreementMember2019-03-012019-03-310001641281bolt:TwoThousandTwentyOneEquityIncentivePlanMemberus-gaap:CommonStockMember2021-01-310001641281us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberbolt:TorayDevelopmentAgreementMember2024-01-012024-03-310001641281us-gaap:LeaseholdImprovementsMember2023-12-310001641281bolt:ChesapeakeMasterLeaseMember2020-08-072020-08-070001641281bolt:TorayDevelopmentAgreementMember2024-01-012024-03-310001641281bolt:ChesapeakeMasterLeaseMember2022-08-012022-08-310001641281us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281bolt:ConsultingAgreementsMembersrt:ScenarioForecastMember2024-07-152024-07-150001641281bolt:GenmabAgreementMemberus-gaap:CommonStockMember2021-05-012021-05-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2024-03-310001641281us-gaap:CommonStockMember2023-01-012023-03-310001641281bolt:EmployeePerformanceAndServiceBasedStockOptionsMember2020-09-012020-09-300001641281us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001641281us-gaap:RetainedEarningsMember2023-12-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001641281us-gaap:CorporateDebtSecuritiesMember2024-03-310001641281us-gaap:SubsequentEventMember2024-05-142024-05-140001641281us-gaap:CommonStockMember2023-03-310001641281bolt:TwoThousandTwentyOneEquityIncentivePlanMember2024-01-010001641281srt:MaximumMemberbolt:GenmabAgreementMember2021-05-012021-05-310001641281us-gaap:CorporateDebtSecuritiesMember2023-12-310001641281us-gaap:CommonStockMember2024-03-310001641281bolt:EmployeePerformanceAndServiceBasedStockOptionsMember2023-01-012023-03-310001641281bolt:ChesapeakeMasterLeaseMember2022-08-310001641281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001641281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281srt:MaximumMemberbolt:ShelfRegistrationAndAtTheMarketEquityOfferingMember2022-03-302022-03-300001641281bolt:InnoventAgreementMember2024-03-310001641281us-gaap:RestrictedStockMember2021-12-012021-12-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-03-310001641281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-3100016412812024-05-070001641281us-gaap:CommercialPaperMember2024-03-310001641281us-gaap:AssetBackedSecuritiesMember2024-03-310001641281bolt:EmployeePerformanceAndServiceBasedStockOptionsMember2024-01-012024-03-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMember2022-12-312022-12-310001641281us-gaap:AssetBackedSecuritiesMember2024-03-310001641281bolt:SeriesTConvertiblePreferredStockMemberbolt:TorayDevelopmentAgreementMember2019-03-012019-03-310001641281us-gaap:OfficeEquipmentMember2024-03-310001641281us-gaap:RetainedEarningsMember2024-03-310001641281us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281us-gaap:AssetBackedSecuritiesMember2023-12-310001641281us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2023-01-012023-03-310001641281bolt:ShelfRegistrationAndAtTheMarketEquityOfferingMemberus-gaap:CommonStockMember2024-01-012024-03-310001641281us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-3100016412812022-12-310001641281bolt:TorayDevelopmentAgreementMember2023-01-012023-03-310001641281us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001641281bolt:InnoventAgreementMember2023-12-310001641281us-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281srt:MinimumMemberus-gaap:SubsequentEventMember2024-05-142024-05-140001641281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2024-03-310001641281us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001641281us-gaap:EquipmentMember2023-12-310001641281us-gaap:AdditionalPaidInCapitalMember2023-12-310001641281us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2023-12-310001641281us-gaap:AdditionalPaidInCapitalMember2022-12-310001641281us-gaap:RetainedEarningsMember2022-12-310001641281us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2024-01-012024-03-310001641281srt:MaximumMemberbolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2021-01-012021-01-310001641281bolt:CommonStockOutstandingSubjectToRepurchaseRelatedToUnvestedEarlyExercisedStockOptionsAndRestrictedStockAwardsMember2023-01-012023-03-310001641281bolt:GenmabAgreementMember2023-12-310001641281srt:MaximumMemberbolt:ChesapeakeMasterLeaseMember2022-08-012022-08-3100016412812023-03-310001641281bolt:ChesapeakeMasterLeaseMember2024-01-012024-03-310001641281bolt:CommonStockOutstandingSubjectToRepurchaseRelatedToUnvestedEarlyExercisedStockOptionsAndRestrictedStockAwardsMember2024-01-012024-03-310001641281us-gaap:OfficeEquipmentMember2023-12-310001641281bolt:TwoThousandTwentyOneEmployeeStockPurchasePlanMemberus-gaap:CommonStockMember2021-01-012021-01-310001641281us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001641281us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001641281bolt:GenmabAgreementMember2024-01-012024-03-310001641281bolt:InnoventAgreementMember2023-01-012023-03-310001641281us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001641281us-gaap:CommercialPaperMember2023-12-310001641281us-gaap:USTreasurySecuritiesMember2023-12-310001641281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2023-12-310001641281bolt:InnoventAgreementMember2024-03-012024-03-310001641281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001641281us-gaap:LeaseholdImprovementsMember2024-03-310001641281srt:MaximumMember2024-01-012024-03-310001641281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310001641281us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001641281bolt:GenmabAgreementMember2023-01-012023-03-310001641281us-gaap:RetainedEarningsMember2024-01-012024-03-310001641281srt:MaximumMemberbolt:ShelfRegistrationAndAtTheMarketEquityOfferingMemberbolt:CowenAndCompanyLlcMemberus-gaap:CommonStockMember2022-03-302022-03-300001641281us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberbolt:GenmabAgreementMember2024-01-012024-03-310001641281us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-31xbrli:pureiso4217:USDxbrli:sharesutr:sqftxbrli:sharesbolt:Employeeiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number 001-39988

 

 

Bolt Biotherapeutics, Inc.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

47-2804636

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

900 Chesapeake Drive

Redwood City, CA

94063

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 665-9295

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.00001 par value

 

BOLT

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YesNo

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YesNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

Accelerated filer

 

 

 

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of May 7, 2024, the registrant had 38,127,740 shares of common stock outstanding.

 

 

 


 

Table of Contents

Page

PART I FINANCIAL INFORMATION

 

Item 1.

Financial Statements (unaudited)

1

 

Condensed Balance Sheets as of March 31, 2024 and December 31, 2023

1

 

Condensed Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2024 and 2023

2

 

Condensed Statements of Stockholders’ Equity for the Three Months Ended March 31, 2024 and 2023

3

 

Condensed Statements of Cash Flows for the Three Months Ended March 31, 2024 and 2023

4

 

Notes to the Condensed Financial Statements

5

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

19

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

 

PART II OTHER INFORMATION

 

Item 1.

Legal Proceedings

27

Item 1A.

Risk Factors

27

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27

Item 3.

Defaults Upon Senior Securities

27

Item 4.

Mine Safety Disclosures

28

Item 5.

Other Information

28

Item 6.

Exhibits

29

 

Signatures

30

 

i


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

BOLT BIOTHERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(Unaudited, in thousands, except share and per share amounts)

 

 

 

March 31,

 

 

December 31,

 

 

 

2024

 

 

2023

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

4,262

 

 

$

10,810

 

Short-term investments

 

 

87,088

 

 

 

91,379

 

Prepaid expenses and other current assets

 

 

3,705

 

 

 

3,519

 

Total current assets

 

 

95,055

 

 

 

105,708

 

Property and equipment, net

 

 

4,499

 

 

 

4,957

 

Operating lease right-of-use assets

 

 

18,347

 

 

 

19,120

 

Restricted cash

 

 

1,765

 

 

 

1,765

 

Long-term investments

 

 

21,461

 

 

 

26,413

 

Other assets

 

 

1,765

 

 

 

1,821

 

Total assets

 

$

142,892

 

 

$

159,784

 

Liabilities and stockholders' equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

2,219

 

 

$

2,987

 

Accrued expenses and other current liabilities

 

 

9,710

 

 

 

12,486

 

Deferred revenue

 

 

1,907

 

 

 

2,201

 

Operating lease liabilities

 

 

2,887

 

 

 

2,782

 

Total current liabilities

 

 

16,723

 

 

 

20,456

 

Operating lease liabilities, net of current portion

 

 

16,680

 

 

 

17,437

 

Deferred revenue, non-current

 

 

5,330

 

 

 

9,107

 

Other long-term liabilities

 

 

 

 

 

43

 

Total liabilities

 

 

38,733

 

 

 

47,043

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

Preferred stock, $0.00001 par value, authorized shares—10,000,000 shares authorized at March 31, 2024 and December 31, 2023; zero shares issued and outstanding at March 31, 2024 and December 31, 2023

 

 

 

 

 

 

Common stock, $0.00001 par value; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 38,127,740 and 38,114,606 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively

 

 

1

 

 

 

1

 

Additional paid-in capital

 

 

479,290

 

 

 

476,988

 

Accumulated other comprehensive (loss) gain

 

 

(36

)

 

 

37

 

Accumulated deficit

 

 

(375,096

)

 

 

(364,285

)

Total stockholders' equity:

 

 

104,159

 

 

 

112,741

 

Total liabilities and stockholders' equity

 

$

142,892

 

 

$

159,784

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

1


 

BOLT BIOTHERAPEUTICS, INC.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited, in thousands, except share and per share amounts)

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Collaboration revenue

 

$

5,274

 

 

$

1,826

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

16,529

 

 

 

14,625

 

General and administrative

 

 

5,837

 

 

 

5,616

 

Total operating expense

 

 

22,366

 

 

 

20,241

 

Loss from operations

 

 

(17,092

)

 

 

(18,415

)

Other income, net

 

 

 

 

 

 

Interest income, net

 

 

1,606

 

 

 

1,435

 

Other income

 

 

4,675

 

 

 

 

Total other income, net

 

 

6,281

 

 

 

1,435

 

Net loss

 

 

(10,811

)

 

 

(16,980

)

Net unrealized (loss) gain on marketable securities

 

 

(73

)

 

 

684

 

Comprehensive loss

 

$

(10,884

)

 

$

(16,296

)

Net loss per share, basic and diluted

 

$

(0.28

)

 

$

(0.45

)

Weighted-average shares outstanding, basic and diluted

 

 

38,068,424

 

 

 

37,684,023

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

2


 

BOLT BIOTHERAPEUTICS, INC.

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

(Unaudited, in thousands, except share amounts)

 

 

 

Three Months Ended March 31, 2024

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

 

Common

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2023

 

 

38,114,606

 

 

$

1

 

 

$

476,988

 

 

$

37

 

 

$

(364,285

)

 

$

112,741

 

Vesting of restricted stock units

 

 

13,134

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,302

 

 

 

 

 

 

 

 

 

2,302

 

Unrealized loss on available-for-sale investments

 

 

 

 

 

 

 

 

 

 

 

(73

)

 

 

 

 

 

(73

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(10,811

)

 

 

(10,811

)

Balance at March 31, 2024

 

 

38,127,740

 

 

$

1

 

 

$

479,290

 

 

$

(36

)

 

$

(375,096

)

 

$

104,159

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

Total

 

 

 

Common

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders'

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2022

 

 

37,797,902

 

 

$

 

 

$

467,513

 

 

$

(919

)

 

$

(295,088

)

 

$

171,506

 

Vesting of restricted stock units

 

 

15,135

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,476

 

 

 

 

 

 

 

 

 

2,476

 

Unrealized gain on available-for-sale investments

 

 

 

 

 

 

 

 

 

 

 

684

 

 

 

 

 

 

684

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16,980

)

 

 

(16,980

)

Balance at March 31, 2023

 

 

37,813,037

 

 

$

 

 

$

469,989

 

 

$

(235

)

 

$

(312,068

)

 

$

157,686

 

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

3


 

BOLT BIOTHERAPEUTICS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net loss

 

$

(10,811

)

 

$

(16,980

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

458

 

 

 

467

 

Stock-based compensation expense

 

 

2,302

 

 

 

2,476

 

Accretion of discount on marketable securities

 

 

(1,033

)

 

 

(852

)

Non-cash lease expense

 

 

773

 

 

 

719

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Prepaid expenses and other assets

 

 

(130

)

 

 

(1,377

)

Accounts payable and accrued expenses

 

 

(3,544

)

 

 

(6,611

)

Operating lease liabilities

 

 

(652

)

 

 

(559

)

Deferred revenue

 

 

(4,071

)

 

 

(683

)

Other long-term liabilities

 

 

(43

)

 

 

1

 

Net cash used in operating activities

 

 

(16,751

)

 

 

(23,399

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Purchase of property and equipment

 

 

 

 

 

(3

)

Purchases of marketable securities

 

 

(23,058

)

 

 

(42,883

)

Maturities of marketable securities

 

 

33,261

 

 

 

71,877

 

Net cash provided by investing activities

 

 

10,203

 

 

 

28,991

 

Net (decrease) increase in cash

 

 

(6,548

)

 

 

5,592

 

Cash, cash equivalents and restricted cash at beginning of year

 

 

12,575

 

 

 

10,809

 

Cash, cash equivalents and restricted cash at end of period

 

$

6,027

 

 

$

16,401

 

Reconciliation of cash, cash equivalents and restricted cash:

 

 

 

 

 

 

Cash and cash equivalents

 

$

4,262

 

 

$

14,836

 

Restricted cash

 

 

1,765

 

 

 

1,565

 

Total cash, cash equivalents and restricted cash

 

$

6,027

 

 

$

16,401

 

Supplemental schedule of non-cash investing and financing activities:

 

 

 

 

 

 

Purchases of property and equipment included in accounts payable and accrued liabilities

 

$

 

 

$

46

 

Deferred offering costs in accounts payable and accrued liabilities

 

$

102

 

 

$

102

 

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

4


 

BOLT BIOTHERAPEUTICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. Description of the Business

Bolt Biotherapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company’s pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development, uniting the targeting precision of antibodies with the power of the innate and adaptive immune system to reprogram the tumor microenvironment for a productive anti-cancer response.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and pursuant to applicable rules and regulations of the SEC regarding interim financial reporting. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. These unaudited condensed financial statements include only normal and recurring adjustments, which are normal in nature, that the Company believes are necessary to a fair statement of the Company’s financial position and the results of its operations and cash flows. The balance sheet as of December 31, 2023 was derived from the audited financial statements as of that date. These interim financial results are not necessarily indicative of results to be expected for the full year or any other period. These unaudited condensed financial statements and the notes accompanying them should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

Risks and Uncertainties

The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on its future financial position or results of operations: risks related to the successful discovery and development of its product candidates, ability to raise additional capital, development of new technological innovations by its competitors, delay or inability to obtain chemical or biological intermediates from such suppliers required for the synthesis of the Company’s product candidates, protection of intellectual property rights, litigation or claims against the Company based on intellectual property rights, and regulatory clearance and market acceptance of the Company’s products.

Global economic and business activities continue to face widespread macroeconomic uncertainties, including pandemics, labor shortages, inflation and monetary supply shifts, recession risks and potential disruptions from major geopolitical conflicts. The Company continues to actively monitor the impact of these macroeconomic factors on its financial condition, liquidity, operations, and workforce. The extent of the impact of these factors on the Company’s operational and financial performance, including its ability to execute its business strategies and initiatives in the expected time frame, will depend on future developments, which are uncertain and cannot be predicted; however, any continued or renewed disruption resulting from these factors could negatively impact the Company’s business.

The Company relies on single source manufacturers and suppliers for the supply of its product candidates. Disruption from these manufacturers or suppliers would have a negative impact on the Company’s business, financial position, and results of operations.

5


 

Liquidity

The Company has incurred net losses and negative cash flows from operations since its inception and anticipates continuing to incur net losses for the foreseeable future. As of March 31, 2024, the Company had cash and cash equivalents and marketable securities of $112.8 million and an accumulated deficit of $375.1 million. Based upon the Company's current operating plans, the Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations for at least the next 12 months following the issuance date of this Quarterly Report on Form 10-Q. The Company will need to raise additional capital to continue the advancement of its programs. In the near term, the Company's primary uses of cash will be to fund the completion of key milestones for clinical programs and to fund its operations, including research and development activities and employee salaries. This includes significant costs relating to clinical trials and manufacture of the Company's product candidates. The Company's uses of cash in the long term will be similar as the Company advances its research and development activities and pays employee salaries. Most pharmaceutical products require larger clinical trials as development progresses, and the Company expects its funding requirements to grow with the advancement of its programs. The Company's long-term funding requirements will depend on many factors, which are uncertain but include its portfolio prioritization decisions and the success of its collaborations. In turn, the Company's ability to raise additional capital through equity or partnering will depend on the general economic environment in which it operates and its ability to achieve key milestones.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to revenue recognition, stock-based compensation and accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from those estimates.

Allowance for Credit Losses

For available-for-sale securities in an unrealized loss position, the Company first assesses whether it intends to sell, or if it is more likely than not that the Company will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, the Company considers the severity of the impairment, any changes in interest rates, market conditions, changes to the underlying credit ratings and forecasted recovery, among other factors. The credit-related portion of unrealized losses, and any subsequent improvements, are recorded in interest income through an allowance account. Any impairment that has not been recorded through an allowance for credit losses is included in other comprehensive income (loss) on the statements of operations and comprehensive loss.

The Company elected the practical expedient to exclude the applicable accrued interest from both the fair value and amortized costs basis of its available-for-sale securities for purposes of identifying and measuring an impairment. Accrued interest receivable on available-for-sale securities is recorded within cash and cash equivalents on the Company's condensed balance sheets. The Company's accounting policy is to not measure an allowance for credit loss for accrued interest receivable and to write-off any uncollectible accrued interest receivable as a reversal of interest income in a timely manner, which the Company considers to be in the period in which it determines the accrued interest will not be collected by the Company.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. As of March 31, 2024 and December 31, 2023, most of the Company’s funds were invested with a registered investment manager and custodied at one financial institution, with operating cash kept at a separate financial institution, and account balances may at times exceed federally insured limits. Management believes that the Company is not subject to unusual or significant credit risk beyond the normal credit risk associated with commercial banking relationships.

6


 

Net Loss Per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, convertible preferred stock, stock options, common stock subject to repurchase related to unvested restricted stock awards and early exercise of stock options are considered potentially dilutive securities. Basic and diluted net loss per share is presented in conformity with the two-class method required for participating securities as the convertible preferred stock is considered a participating security because it participates in dividends with common stock. The Company also considers the shares issued upon the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have non-forfeitable dividend rights in the event a dividend is paid on common stock. The holders of all series of convertible preferred stock and the holders of early exercised shares subject to repurchase do not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods presented as potentially dilutive securities were anti-dilutive.

Recent Accounting Standards

From time to time, new accounting standards are issued by the Financial Accounting Standards Board (the “FASB”), or other standard setting bodies and adopted by the Company as of the specified effective date. There have been no new accounting pronouncements issued nor adopted during the three months ended March 31, 2024 that are of significance to the Company’s financial position or results of operations.

3. Fair Value Measurements and Fair Value of Financial Instruments

The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

During the three months ended March 31, 2024, financial assets measured on a recurring basis consist of cash invested in money market accounts, short-term investments, and long-term investments. The fair value of short- and long-term investments is based upon market prices quoted on the last day of the fiscal period or other observable market inputs. The Company obtains pricing information from its investment manager and generally determines the fair value of investment securities using standard observable inputs, including reported trades, broker/dealer quotes, bids and/or offers.

There were no transfers within the hierarchy during the three months ended March 31, 2024 or 2023.

7


 

Marketable securities, all of which are classified as available-for-sale securities, consisted of the following at March 31, 2024 and December 31, 2023 (in thousands):

 

 

 

March 31, 2024

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Asset-backed securities

 

$

18,918

 

 

$

3

 

 

$

(12

)

 

$

18,909

 

U.S. treasury securities

 

 

40,110

 

 

 

5

 

 

 

(15

)

 

 

40,100

 

Other government agency securities

 

 

8,939

 

 

 

 

 

 

(23

)

 

 

8,916

 

Commercial paper

 

 

17,070

 

 

 

1

 

 

 

(8

)

 

 

17,063

 

Corporate debt securities

 

 

23,548

 

 

 

21

 

 

 

(8

)

 

 

23,561

 

Total

 

$

108,585

 

 

$

30

 

 

$

(66

)

 

$

108,549

 

 

 

 

December 31, 2023

 

 

 

Amortized

 

 

Unrealized

 

 

Unrealized

 

 

Estimated

 

 

 

Cost

 

 

Gains

 

 

Losses

 

 

Fair Value

 

Asset-backed securities

 

$

17,347

 

 

$

10

 

 

$

(15

)

 

$

17,342

 

U.S. treasury securities

 

 

43,924

 

 

 

34

 

 

 

(11

)

 

 

43,947

 

Other government agency securities

 

 

13,371

 

 

 

 

 

 

(15

)

 

 

13,356

 

Commercial paper

 

 

20,351

 

 

 

4

 

 

 

(10

)

 

 

20,345

 

Corporate debt securities

 

 

22,763

 

 

 

41

 

 

 

(2

)

 

 

22,802

 

Total

 

$

117,756

 

 

$

89

 

 

$

(53

)

 

$

117,792

 

 

As of March 31, 2024, the unrealized losses for available-for-sale investments were primarily due to changes in interest rates and not due to increased credit risks associated with specific securities. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost bases of the investments. The Company does not currently intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at the time of maturity. As of March 31, 2024, no allowance for credit losses was recorded and the Company did not recognize any impairment losses related to investments.

The tables below show the gross unrealized losses and fair value of the Company's available-for-sale securities with unrealized losses that are not deemed to have credit losses (in thousands), aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position at March 31, 2024 and December 31, 2023, respectively:

 

 

 

March 31, 2024

 

 

 

Less Than 12 Months

 

 

More Than 12 Months

 

 

Total

 

 

 

Estimated

 

 

Unrealized

 

 

Estimated

 

 

Unrealized

 

 

Estimated

 

 

Unrealized

 

 

 

Fair Value

 

 

Losses

 

 

Fair Value

 

 

Losses

 

 

Fair Value

 

 

Losses

 

Asset-backed securities

 

$

5,715

 

 

$

(1

)

 

$

13,194

 

 

$

(11

)

 

$

18,909

 

 

$

(12

)

U.S. treasury securities

 

 

28,220

 

 

 

(3

)

 

 

11,880

 

 

 

(12

)

 

 

40,100

 

 

 

(15

)

Other government agency securities

 

 

 

 

 

 

 

 

8,916

 

 

 

(23

)

 

 

8,916

 

 

 

(23

)

Commercial paper

 

 

17,063

 

 

 

(8

)

 

 

 

 

 

 

 

 

17,063

 

 

 

(8

)

Corporate debt securities

 

 

13,419

 

 

 

(6

)

 

 

10,142

 

 

 

(2

)

 

 

23,561

 

 

 

(8

)

Total

 

$

64,417

 

 

$

(18

)

 

$

44,132

 

 

$

(48

)

 

$

108,549

 

 

$

(66

)

 

 

 

December 31, 2023

 

 

 

Less Than 12 Months

 

 

More Than 12 Months

 

 

Total

 

 

 

Estimated

 

 

Unrealized

 

 

Estimated

 

 

Unrealized

 

 

Estimated

 

 

Unrealized

 

 

 

Fair Value

 

 

Losses

 

 

Fair Value

 

 

Losses

 

 

Fair Value

 

 

Losses

 

Asset-backed securities

 

$

4,686

 

 

$

-

 

 

$

12,656

 

 

$

(15

)

 

$

17,342

 

 

$

(15

)

U.S. treasury securities

 

 

34,104

 

 

 

 

 

 

9,843

 

 

 

(11

)

 

 

43,947

 

 

 

(11

)

Other government agency securities

 

 

2,477

 

 

 

(1

)

 

 

10,879

 

 

 

(14

)

 

 

13,356

 

 

 

(15

)

Commercial paper

 

 

20,345

 

 

 

(10

)

 

 

 

 

 

 

 

 

20,345

 

 

 

(10

)

Corporate debt securities

 

 

9,566

 

 

 

(1

)

 

 

13,236

 

 

 

(1

)

 

 

22,802

 

 

 

(2

)

Total

 

$

71,178

 

 

$

(12

)

 

$

46,614

 

 

$

(41

)

 

$

117,792

 

 

$

(53

)

 

8


 

 

Accrued interest receivable on available-for-sale securities were $0.3 million at March 31, 2024 and December 31, 2023, which are recorded in cash and cash equivalents line item on the Company's condensed balance sheets. The Company has not written off any accrued interest receivables for the three months ended March 31, 2024.

As of March 31, 2024 and December 31, 2023, the fair values of the Company’s assets, which are measured at fair value on a recurring basis, were determined using the following inputs (in thousands):

 

 

 

March 31, 2024

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

2,395

 

 

$

2,395

 

 

$

 

 

$

 

Asset-backed securities

 

 

18,909

 

 

 

 

 

 

18,909

 

 

 

 

U.S. treasury securities

 

 

40,100

 

 

 

26,185

 

 

 

13,915

 

 

 

 

Other government agency securities

 

 

8,916

 

 

 

 

 

 

8,916

 

 

 

 

Commercial paper

 

 

17,063

 

 

 

 

 

 

17,063

 

 

 

 

Corporate debt securities

 

 

23,561

 

 

 

 

 

 

23,561

 

 

 

 

Total

 

$

110,944

 

 

$

28,580

 

 

$

82,364

 

 

$

 

 

 

 

December 31, 2023

 

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Money market funds

 

$

8,641

 

 

$

8,641

 

 

$

 

 

$

 

Asset-backed securities

 

 

17,342

 

 

 

 

 

 

17,342

 

 

 

 

U.S. treasury securities

 

 

43,947

 

 

 

33,001

 

 

 

10,946

 

 

 

 

Other government agency securities

 

 

13,356

 

 

 

 

 

 

13,356

 

 

 

 

Commercial paper

 

 

20,345

 

 

 

 

 

 

20,345

 

 

 

 

Corporate debt securities

 

 

22,802

 

 

 

 

 

 

22,802

 

 

 

 

Total

 

$

126,433

 

 

$

41,642

 

 

$

84,791

 

 

$

 

 

 

4. Balance Sheet Components

Property and Equipment, net

Property and equipment, net, consist of the following (in thousands):

 

 

 

March 31,
2024

 

 

December 31,
2023

 

Laboratory equipment

 

$

10,038

 

 

$

10,038

 

Office equipment

 

 

386

 

 

 

386

 

Leasehold improvements

 

 

286

 

 

 

285

 

Total property and equipment

 

 

10,710

 

 

 

10,709

 

Less accumulated depreciation and amortization

 

 

(6,211

)

 

 

(5,752

)

Total

 

$

4,499

 

 

$

4,957

 

 

Depreciation expense related to property and equipment was $0.5 million for each of the three months ended March 31, 2024 and 2023.

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

 

 

 

March 31,
2024

 

 

December 31,
2023

 

Accrued research and development

 

$

6,194

 

 

$

6,092

 

Accrued compensation

 

 

2,703

 

 

 

5,820

 

Accrued other

 

 

813

 

 

 

574

 

Total

 

$

9,710

 

 

$

12,486

 

 

9


 

5. Collaborations

Joint Development and License Agreement with Toray Industries, Inc.

In March 2019, the Company entered into a Joint Development and License Agreement (the “Toray Agreement”) with Toray Industries, Inc. (“Toray”) to jointly develop and commercialize a Boltbody™ immune-stimulating antibody conjugate (“ISAC”) containing Toray’s proprietary antibody to treat cancer. The Company determined that the Toray Agreement is a contract with a customer and should be accounted for under ASC 606. In conjunction with the Toray Agreement, the Company entered into a Series T Convertible Preferred Stock Purchase Agreement (the “Series T Agreement”) for the issuance of 717,514 shares of Series T convertible preferred stock to Toray. These contracts have been evaluated together and the consideration in excess of the fair value of the Series T convertible preferred stock of $1.5 million has been allocated to the Toray Agreement and included in the total consideration for collaboration revenue. In February 2021, in connection with the Company’s initial public offering ("IPO"), all outstanding shares of Series T convertible preferred stock were converted into shares of the Company’s common stock.

In the Toray Agreement, the Company has identified one bundled performance obligation which includes the license rights, research and development services and services associated with participation on a joint steering committee. The transaction price includes the $1.5 million allocated from the Series T convertible preferred stock and $1.9 million of estimated variable consideration related to compensation for research and development services at the agreed upon full-time employee rate and third-party costs. Collaboration revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using an input method as a measure of progress towards satisfying the performance obligation, which is based on project hours. Amounts are billed based on estimated variable consideration in the quarter ahead of performance and are trued up on the subsequent quarter’s invoice following the work performed. The cumulative effect of revisions to estimated hours to complete the Company’s performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. As of March 31, 2024, receivables of $0.2 million related to research and development services performed under the Toray Agreement were recorded as part of the prepaid expenses and other current assets line item on the balance sheet. Deferred revenue allocated to the unsatisfied performance obligation is recorded as a contract liability on the balance sheet and will be recognized over time as the services are performed. As of March 31, 2024, contract liabilities totaling $1.1 million at period-end were recorded in deferred revenue with $0.5 million in current liabilities and $0.6 million in non-current liabilities on the balance sheet based on the forecasted periods of performance.

The following table presents changes in the Company contract liability (in thousands):

 

Balance at December 31, 2023

 

$

1,502

 

Addition—amount billed or accrued for research and development services

 

 

182

 

Revenue recognized

 

 

(576

)

Balance at March 31, 2024

 

$

1,108

 

The Company recorded $0.6 million and zero revenue during the three months ended March 31, 2024 and 2023, respectively. The Toray Agreement includes both fixed and variable considerations. Under the Toray Agreement, the Company will be compensated for early-stage development and manufacturing activities based on agreed full-time equivalent rates and actual out-of-pocket costs incurred through the completion of the first Phase 1 clinical trial for the lead product candidate and Toray is entitled to reimbursement for 50% of such development costs from the Company’s share of revenues collected from the sale or licensing of collaboration products. Although the legal term of the agreement is until collaboration products are no longer sold in the territories covered under the agreement, the parties have present enforceable rights and obligations through the end of the first Phase 1 clinical trial, after which both parties can opt out of continued development under the agreement. As such, the accounting term of the Toray Agreement was considered to terminate upon completion of the first Phase 1 clinical trial. After the conclusion of the first Phase 1 clinical trial, the parties will share equally all costs of development activities necessary for obtaining regulatory approval of collaboration products in the indications in the territories covered under the agreement, unless either party elects to opt out of its co-funding obligations or reduce them by half, which election can be on a region-by-region basis or for the territories covered under the agreement as a whole. Such optional additional items will be accounted for as contract modifications when development advances past certain milestones and the parties both exercise their opt-in rights.

10


 

Oncology Research and Development Collaboration with Genmab A/S

In May 2021, the Company entered into a License and Collaboration Agreement (the “Genmab Agreement”) with Genmab A/S (“Genmab”). Together, the companies will evaluate Genmab antibodies and bispecific antibody engineering technologies in combination with the Company’s Boltbody ISAC technology platform, with the goal of discovering and developing next-generation bispecific ISACs for the treatment of cancer. Under this research collaboration, the companies will evaluate multiple bispecific ISAC concepts to identify up to three clinical candidates for development. Genmab will fund the research, along with the preclinical and clinical development of these candidates through initial clinical proof of concept. Under the Genmab Agreement, the Company received an upfront payment of $10.0 million. The Company has determined that the Genmab Agreement is a contract with a customer and should be accounted for under ASC 606. In conjunction with the Genmab Agreement, the Company entered into a stock purchase agreement (the “Genmab SPA”) for the issuance of 821,045 shares of the Company’s common stock to Genmab for a total purchase price of $15.0 million. These contracts have been evaluated together and the consideration in excess of the fair value of the common stock of $1.4 million has been allocated to the Genmab Agreement and included in the total consideration for collaboration revenue.

In the Genmab Agreement, the Company has identified one bundled performance obligation that includes the license rights, research and development services, and services associated with participation on a joint research committee. The transaction price includes the $10.0 million upfront payment, the $1.4 million allocated from the Genmab SPA, and $30.9 million of estimated variable consideration related to compensation for research and development services at the agreed upon full-time employee rate and third-party costs. Collaboration revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using an input method as a measure of progress towards satisfying the performance obligation, which is based on project hours. Compensation for the research and development services are billed in the quarter based on actual hours incurred to satisfy the performance obligation. The cumulative effect of revisions to estimated hours to complete the Company’s performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. As of March 31, 2024, receivables of $0.7 million related to research and development services performed under the Genmab Agreement were recorded as part of the prepaid expenses and other current assets line item on the balance sheet. Deferred revenue allocated to the unsatisfied performance obligation is recorded as a contract liability on the balance sheet and will be recognized over time as the services are performed. As of March 31, 2024, contract liabilities totaling $6.1 million were recorded in deferred revenue with $1.4 million in current liabilities and $4.7 million in non-current liabilities on the balance sheet based on the forecasted periods of performance.

The following table presents changes in the Company contract liability (in thousands):

 

Balance at December 31, 2023

 

$

6,664

 

Addition—amount billed for research and development services

 

 

691

 

Revenue recognized

 

 

(1,225

)

Balance at March 31, 2024

 

$

6,130

 

The Company recorded $1.2 million and $1.0 million in revenue earned during the three months ended March 31, 2024 and 2023, respectively, based on services performed under the Genmab Agreement during the period. Under the Genmab Agreement, the Company will be compensated for research and development services at the agreed upon full-time employee rate and third-party costs through initial clinical proof of concept of the therapeutic candidates, which also represents the period of time both parties have enforceable rights and obligations. As such, the accounting term of the Genmab Agreement was considered to terminate upon completion of the initial clinical proof of concept of the therapeutic candidates, after which both parties can exercise their respective program opt-in rights. The Genmab Agreement includes optional additional items which will be accounted for as contract modifications after initial clinical proof of concept of the therapeutic candidates. With respect to each candidate for which a party has exercised its program opt-in rights and has exclusive global rights, the other party is eligible to receive potential development and sales-based milestone payments and tiered royalties, subject to certain customary reductions, the amount of all such considerations will vary based on the market potential of the applicable territory for which such party has exercised its program opt-in rights. Under the Genmab Agreement, the Company is eligible to receive total potential milestone payments of up to $125.0 million in development milestones and $160.0 million in sale milestones per therapeutic candidate exclusively developed and commercialized by Genmab, along with tiered royalties at rates from a single-digit to mid-teens percentage based on net sales of each therapeutic candidate. However, given the current phase of development of therapeutic candidates under the Genmab Agreement, the Company cannot estimate the probability or timing of achieving these milestones, and, therefore, has excluded all milestone and royalty payments from the transaction prices of the agreement.

11


 

Oncology Research and Development Collaboration with Innovent Biologics, Inc.

In March 2024, the Company entered into an amended and restated license and collaboration agreement with Innovent Biologics, Inc. (the “Amended Innovent Agreement”), which amends the original license and collaboration agreement with Innovent Biologics, Inc. ("Innovent") dated August 25, 2021 (the “Original Innovent Agreement”). Under the Original Innovent Agreement, the Company and Innovent leveraged Innovent’s proprietary therapeutic antibody portfolio and antibody discovery capability against undisclosed oncology targets in combination with the Company's Boltbody ISAC technology and myeloid biology expertise to create new candidates for cancer treatments. Innovent funded the initial research, along with the preclinical development of these candidates through the contract modification date. Under the Original Innovent Agreement, the Company received an upfront payment of $5.0 million and was compensated for research and development services at the agreed upon full-time employee rate and third-party costs.

As part of the Amended Innovent Agreement, Innovent paid the Company a one-time payment of $4.7 million to be relieved from certain future funding and developmental obligations under the Original Innovent Agreement. Additionally, the Company secured exclusive worldwide rights to ISAC programs utilizing specified antibodies against two tumor antigen targets and assumed all future development and commercialization costs for any such ISAC program. Under the Amended Innovent Agreement, the Company has the right, but not the obligation, to further develop and commercialize the ISAC programs. Innovent and its affiliates are eligible to receive total potential milestones payments of up to $112.7 million, as well as royalties in low single digits on global net sales.

The Company determined that the Amended Innovent Agreement no longer meets the criteria under ASC 606. Therefore, $2.5 million of deferred revenue allocated to the unsatisfied performance obligation as of the contract modification date, was recognized as revenue and the $4.7 million one-time payment received was recognized as other income on the condensed statement of operations and comprehensive loss for the three months ended March 31, 2024.

The following table presents changes in the Company contract liability (in thousands):

 

Balance at December 31, 2023

 

$

3,142

 

Addition—amount billed for research and development services

 

 

331

 

Revenue recognized

 

 

(3,473

)

Balance at March 31, 2024

 

$

 

The Company recorded $3.5 million and $0.8 million in revenue earned during the three months ended March 31, 2024 and 2023, respectively, based on services performed to satisfy the performance obligation under the Innovent collaboration during the periods.

Oncology Clinical Trial Collaboration and Supply Agreement with Bristol-Myers Squibb

In September 2021, the Company entered into a clinical collaboration and supply agreement with Bristol-Myers Squibb Company (“BMS”) to study trastuzumab imbotolimod in combination with BMS’s PD-1 checkpoint inhibitor nivolumab, for the treatment of HER2-expressing solid tumors (the “BMS Agreement”). Under the BMS Agreement, BMS granted the Company a non-exclusive, non-transferable, royalty-free license (with a right to sublicense) under its intellectual property to use nivolumab in a clinical trial for a combination therapy of nivolumab and the Company’s proprietary compound, trastuzumab imbotolimod, and has agreed to supply nivolumab at no cost to the Company and the Company will sponsor, fund and conduct the initial Phase 1/2 clinical trial in accordance with an agreed-upon protocol. Both parties will own the study data produced in the clinical trial, other than study data related solely to nivolumab, which will belong solely to BMS, or study data related solely to trastuzumab imbotolimod, which will belong solely to the Company. The parties may conduct additional clinical trials on the combined therapy which may be sponsored and funded by one party, or jointly funded. Given the terms of the BMS Agreement, the Company has concluded that it is not within the scope of ASC 808 or ASC 606. Any relevant costs arising from the clinical trial will be expensed as incurred and recorded in research and development expenses. The Company initiated the clinical trial for the combination therapy of nivolumab and trastuzumab imbotolimod in the fourth quarter of 2021.

12


 

Clinical Supply Agreement with F. Hoffmann-La Roche Ltd

In September 2022, the Company entered into a clinical supply agreement with Roche to study trastuzumab imbotolimod in combination with Roche’s pertuzumab (Perjeta®), a compound approved for the treatment of HER2-positive breast cancer (the "Roche Agreement"). Under the Roche Agreement, Roche granted the Company a non-exclusive, non-sublicenseable, royalty-free license under its intellectual property to use pertuzumab in a clinical trial for a combination therapy of pertuzumab and the Company's proprietary compound, trastuzumab imbotolimod, and has agreed to supply pertuzumab at no cost to the Company. The Company will sponsor, fund and conduct the initial Phase 2 clinical trial in accordance with an agreed-upon protocol. Both parties will own the study data produced in the clinical trial, other than study data related solely to pertuzumab, which will belong solely to Roche, or study data related solely to trastuzumab imbotolimod, which will belong solely to the Company. The parties may conduct additional clinical trials on the combined therapy which may be sponsored and funded by one party, or jointly funded. Given the terms of the Roche Agreement, the Company has concluded that it is not within the scope of ASC 808 or ASC 606. Any relevant costs arising from the clinical trial will be expensed as incurred and recorded in research and development expenses.

6. Commitments and Contingencies

Leases

The Company has operating leases for its corporate office, laboratory and vivarium space in Redwood City, California. On August 7, 2020, the Company executed a non-cancellable lease agreement for 71,646 square feet of space (the “Chesapeake Master Lease”), which consist of 25,956 square feet under an existing lease and 45,690 square feet of additional space, for its corporate office, laboratory and vivarium space in Redwood City, California. The Chesapeake Master Lease has an initial term of ten years from the commencement date, with an option to extend the lease for an additional eight-year term. The Chesapeake Master Lease contains rent escalation, and the Company is also responsible for certain operating expenses and taxes throughout the lease term. In addition, the Company is entitled to up to $4.8 million of tenant improvement allowance, which was paid directly by the landlord to various vendors. Upon execution of the non-cancellable lease agreement, the Company took control of 10,000 square feet of space, which was subleased as further described below. The remaining 35,690 square feet of additional office, laboratory and vivarium space commenced in June 2021.

In connection with the execution of the Chesapeake Master Lease, the Company entered into two operating lease agreements to sublease portions of the premises to two unrelated third parties. The first sublease agreement, to sublease 10,000 square feet, commenced in August 2020 and expired on August 31, 2022. The second sublease agreement, to sublease 10,500 square feet, commenced in June 2021 and expired on July 31, 2023. In August 2022, the second sublease agreement was amended to expand the subleased premises to 11,655 square feet in the first year and further increase to 13,743 square feet in the second year. In addition, the expiration date of the second sublease was also amended to the expiration date of the Chesapeake Master Lease. The subtenant has an early termination option with the early termination date no earlier than September 30, 2024, and no option to extend the sublease term. Rent for the second sublease is subject to scheduled annual increases and the subtenant is responsible for certain operating expenses and taxes throughout the term under the sublease agreement. Sublease income under the two sublease agreements was approximately $0.2 million for each of the three months ended March 31, 2024 and 2023.

At March 31, 2024 and December 31, 2023, finance right-of-use leases were used to finance capital equipment such as printers or ozone generators, and are immaterial.

The weighted-average remaining lease term and discount rate related to the Company’s lease liabilities as of March 31, 2024 were 6.5 years and 11.1%, respectively, for the operating leases. The weighted-average remaining lease term and discount rate related to the Company’s lease liabilities as of December 31, 2023 were 6.7 years and 11.1%, respectively, for the operating leases. The Company lease discount rates are based on estimates of its incremental borrowing rate, as the discount rates implicit in the Company’s leases cannot be readily determined. As the Company does not have any outstanding debt, the Company estimates the incremental borrowing rate based on its estimated credit rating and available market information.

The components of lease expense were as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Total operating lease cost

 

$

1,121

 

 

$

1,121

 

 

13


 

Supplemental cash flow information related to leases was as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2024

 

 

2023

 

Operating cash flows from operating leases

 

$

1,201

 

 

$

1,162

 

 

The following is a schedule by year for future maturities of the Company’s operating lease liabilities and sublease income to be received as of March 31, 2024 (in thousands):

 

 

 

Operating Leases

 

 

Sublease Income

 

2024

 

$

3,685

 

 

$

363

 

2025

 

 

4,340

 

 

 

 

2026

 

 

3,484

 

 

 

 

2027

 

 

3,602

 

 

 

 

2028

 

 

3,724

 

 

 

 

Thereafter

 

 

9,514

 

 

 

 

Total minimum lease payments/sublease income

 

 

28,349

 

 

 

363

 

Less imputed interest

 

 

(8,782

)

 

 

 

Total

 

$

19,567

 

 

$

363

 

 

 

 

 

 

 

 

 

Supply Agreement

The Company has entered into a supply agreement with EirGenix, Inc., pursuant to which the Company may be required to pay milestone payments upon the achievement of specified regulatory milestones. The agreement is cancellable by the Company upon delivering the appropriate prior written notice. At March 31, 2024, potential future milestone payments under this agreement were up to $2.0 million.

Guarantees and Indemnifications

In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of March 31, 2024, the Company did not have any material indemnification claims that were probable or reasonably possible and, consequently, had not recorded related liabilities.

Other Commitments

The Company enters into agreements in the normal course of business, including with contract research organizations for clinical trials, contract manufacturing organizations for certain manufacturing services, and vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice.

Legal Proceedings

The Company is subject to claims and assessments from time to time in the ordinary course of business but is not aware of any such matters, individually or in the aggregate, that will have a material adverse effect on the Company’s financial position, results of operations or cash flows.

14


 

7. Common Stock

Shelf Registration and At-The-Market Equity Offering

On March 30, 2022, the Company filed a shelf registration statement on Form S-3 (the "Registration Statement"). Pursuant to the Registration Statement, the Company may offer and sell securities having an aggregate public offering price of up to $250.0 million. In connection with the filing of the Registration Statement, the Company also entered into a sales agreement with Cowen and Company, LLC ("Cowen"), as sales agent or principal, pursuant to which the Company may issue and sell shares of its common stock for an aggregate offering price of up to $75.0 million under an at-the-market (the “ATM”) offering program. Pursuant to the ATM, the Company will pay Cowen a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock. The Company is not obligated to make any sales of shares of its common stock under the ATM. As of March 31, 2024, no shares of the Company's common stock have been sold under this ATM.

8. Stock-Based Compensation

2021 Equity Incentive Plan and 2021 Employee Stock Purchase Plan

In January 2021, the Company’s board of directors adopted the 2021 Equity Incentive Plan (the “2021 Plan”) and the Company’s stockholders approved the 2021 Plan. The 2021 Plan authorized issuance of up to 8,075,000 shares of common stock and it became effective upon the execution of the underwriting agreement for the Company’s IPO. In addition, the number of shares of common stock reserved for issuance under the 2021 Plan automatically increases on the first day of January of each calendar year that commences after the 2021 Plan became effective and continuing through and including January 1, 2031, in an amount equal to 5% of the total number of shares of the Company’s common stock outstanding on December 31, or a lesser number of shares determined by the Company's board of directors or compensation committee. As a result, common stock reserved for issuance under the 2021 Plan was increased by 1,905,730 shares on January 1, 2024.

In addition, in January 2021, the Company’s board of directors and stockholders adopted the 2021 Employee Stock Purchase Plan (the “ESPP”). The ESPP authorized issuance of up to 420,000 shares of common stock and it became effective upon the execution of the underwriting agreement for the Company’s IPO. The 2021 ESPP permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation. Employees purchase shares of common stock at a price per share equal to 85% of the lower of the fair market value at the start or end of six-month purchase periods within the two-year offering period. In addition, the number of shares of common stock reserved for issuance under the 2021 ESPP automatically increases on January 1 of each calendar year that commences after the ESPP became effective and continuing through and including January 1, 2031, by the lesser of (1)